Atomo Diagnostics Ltd. (AT1) Price & Analysis

Compare

7 Followers

AT1 Stock Chart & Stats

AU$0.04

>-AU$0.01(-5.00%)

At close: Jan 09 4:00 PM EST

AU$0.04

>-AU$0.01(-5.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.05

Previous CloseN/A

Volume312.94K

Average Volume (3M)1.80M

Market Cap

AU$33.22M

Enterprise ValueAU$28.56M

Total Cash (Recent Filing)AU$3.22M

Total Debt (Recent Filing)AU$185.10K

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding810,175,300

10 Day Avg. Volume984,499

30 Day Avg. Volume1,797,539

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.30

Price to Sales (P/S)2.39

P/FCF Ratio-4.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Integrated PlatformAtomo's proprietary integrated blood-collection and RDT device is a durable competitive asset: it bundles lancet, collection and delivery which increases partner convenience and product stickiness. As a hardware supplier to test manufacturers, this platform can sustain recurring B2B demand and create switching costs as partners embed the device into test kits and programs.

Low Leverage / Stable Capital StructureMinimal leverage gives Atomo financial flexibility over the medium term: low interest burden and a stronger ability to fund operations, R&D or commercialization without immediate debt servicing pressure. This balance sheet conservatism supports resilience during revenue cyclicality and provides runway to restructure or invest in scaling initiatives.

Healthy Product-level Gross MarginsA gross margin near 47% indicates attractive unit economics for the device business, implying that once volumes increase the company can generate operating leverage. Durable product-level profitability supports the case that scale, cost control and tighter SG&A could translate these margins into sustainable operating profits over several quarters if revenue trends reverse.

Bears Say

Declining RevenueA persistent revenue decline undermines the benefits of attractive unit economics and makes fixed-cost absorption harder. For a B2B hardware supplier, falling top line over multiple periods suggests adoption or demand issues with partners or programs, reducing scale economics and making long-term recovery dependent on new contract wins or expanded partner uptake.

Deep Negative ProfitabilityExtremely negative EBIT and net margins indicate structural operating losses that are not explained by COGS alone; high SG&A or R&D fixed costs appear to overwhelm gross profits. This level of loss requires sustained revenue growth or significant cost restructuring to restore profitability, posing a lasting challenge to shareholder returns.

Deteriorating Cash GenerationNegative and worsening operating and free cash flow reduces strategic options: it constrains the firm's ability to fund inventory, commercial expansion or product development internally. Over a multi-month horizon this raises the probability of needing external financing, which could dilute shareholders or limit the company's capacity to support partner-led scaling.

Atomo Diagnostics Ltd. News

Atomo Wins A$630,000 Order for Government-Backed HIV Self-Testing Program

The latest update is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics has secured a material...

15d ago

AT1

Atomo Wins Second Major Global Fund–Backed Order for HIV Self-Tests

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has secured a A$416,000 purchase order...

21d ago

AT1

Atomo Diagnostics Sets Date for Q2 FY26 Results and Investor Webinar

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics has scheduled the release of its...

29d ago

AT1

Atomo Diagnostics Wins Exclusive Global Licence for Rapid Liver Function Test on Pascal Platform

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has secured an exclusive global licence...

1M ago

AT1

Atomo Wins $502,000 HIV Self-Test Order Backed by Global Fund

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics Limited has secured a material purchase...

1M ago

AT1

Atomo Diagnostics Grants Options to Director Following Shareholder Approval

An announcement from Atomo Diagnostics Ltd. ( ($AU:AT1) ) is now available. Atomo Diagnostics Ltd. announced a change...

2M ago

AT1

Atomo Diagnostics Issues New Equity Securities Under Employee Incentive Scheme

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics Ltd. has announced the issuance of...

2M ago

AT1

Atomo Diagnostics Addresses ASX Query on Unusual Trading Activity

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has issued an update. Atomo Diagnostics Ltd. has responded to an ASX...

3M ago

AT1

Atomo Diagnostics Adopts Amended Constitution

The latest announcement is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics Ltd. announced the adoption...

4M ago

AT1

Atomo Diagnostics Reports Successful 2025 AGM Results

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics Limited announced the results of its...

4M ago

AT1

AT1 FAQ

What was Atomo Diagnostics Ltd.’s price range in the past 12 months?

Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.

What is Atomo Diagnostics Ltd.’s market cap?

Atomo Diagnostics Ltd.’s market cap is AU$33.22M.

When is Atomo Diagnostics Ltd.’s upcoming earnings report date?

Atomo Diagnostics Ltd.’s upcoming earnings report date is Apr 23, 2026 which is in 62 days.

How were Atomo Diagnostics Ltd.’s earnings last quarter?

Currently, no data Available

Is Atomo Diagnostics Ltd. overvalued?

According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Atomo Diagnostics Ltd. pay dividends?

Atomo Diagnostics Ltd. does not currently pay dividends.

What is Atomo Diagnostics Ltd.’s EPS estimate?

Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atomo Diagnostics Ltd. have?

Atomo Diagnostics Ltd. has 810,175,300 shares outstanding.

What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?

Currently, no hedge funds are holding shares in AU:AT1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atomo Diagnostics Ltd. Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:AT1 Sentiment 100%
Sector Average 70%

Technicals

Fundamentals

Return on Equity

-58.27%

Trailing 12-Months

Asset Growth

-18.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atomo Diagnostics Ltd.

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.